Breast Cancer Liquid Biopsy Testing Devices Market to Grow with a CAGR of 17.20% through 2030
MRD monitoring, regulatory approvals, and industry
collaboration is expected to drive the Global Breast Cancer Liquid Biopsy
Testing Devices Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Breast
Cancer Liquid Biopsy Testing Devices Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030”, the Global Breast
Cancer Liquid Biopsy Testing Devices Market stood at USD 835.36 million in 2024 and is anticipated to grow with a CAGR of 17.20% in the forecast period,
2026-2030.
In the healthcare industry, patient preferences are increasingly driving innovation and shaping the future of diagnostics and treatment. One notable area where this phenomenon is making a significant impact is the global breast cancer liquid biopsy testing devices market. Patients are now exercising their right to choose less invasive, more comfortable, and patient-centric diagnostic methods.
Traditionally, breast cancer diagnosis and monitoring often involve invasive procedures, such as tissue biopsies. These procedures can be painful, distressing, and have associated risks. In contrast, liquid biopsy testing devices require only a simple blood sample, making the process far less invasive and intimidating. Patients, recognizing the comfort and convenience offered by this approach, are increasingly opting for liquid biopsies over traditional methods.
The fear and anxiety associated with cancer diagnosis and treatment are well-documented. Liquid biopsy testing devices help alleviate some of this anxiety. The non-invasive nature of these tests reduces the psychological burden on patients, making them more likely to comply with recommended diagnostic and monitoring schedules. When patients are more comfortable with the diagnostic process, they are more likely to adhere to their treatment plans, improving their overall care and prognosis.
Patient preferences are increasingly geared towards monitoring and managing their health proactively. Liquid biopsy testing devices provide a tool for regular monitoring of breast cancer progression and treatment effectiveness. This enables patients to actively participate in their care, making informed decisions with their healthcare providers. The ability to monitor their health more closely is a significant factor contributing to the growth of the liquid biopsy market.
Modern healthcare is increasingly moving towards personalized medicine, tailoring treatments to the individual genetic makeup of the patient. Liquid biopsy testing devices play a pivotal role in this trend. By identifying specific genetic mutations and biomarkers present in the patient's tumor, these devices enable healthcare professionals to select the most effective targeted therapies. Patients appreciate the precision of these treatments and are more likely to opt for liquid biopsy-based diagnostic methods.
Patients are increasingly aware of the importance of early detection and timely interventions in achieving the best possible treatment outcomes. Liquid biopsy testing devices offer the opportunity for earlier diagnosis and treatment adjustments based on real-time monitoring. This not only improves outcomes but also gives patients a sense of empowerment and control over their health.
Patient preferences are powerful drivers in the healthcare industry. As patients become more informed and vocal about their choices, the demand for non-invasive, patient-centric diagnostic methods, such as liquid biopsies, continues to grow. This increased demand is fostering innovation and expansion in the global breast cancer liquid biopsy testing devices market.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Breast Cancer Liquid Biopsy Testing Devices Market”
The Global Breast Cancer Liquid Biopsy Testing Devices
Market is segmented into offerings, circulating biomarker, application,
regional distribution, and company.
Based on circulating biomarker, Circulating Tumor DNA (ctDNA) is the fastest-growing segment in the Global Breast Cancer Liquid Biopsy Testing Devices Market during the forecast period. As a game-changer in cancer diagnostics, ctDNA offers a non-invasive, highly sensitive method for detecting breast cancer mutations. With advancements in liquid biopsy technology, it enables real-time tumor monitoring and treatment assessment. Its ability to identify a broad spectrum of genetic alterations aligns with the rise of personalized medicine, enhancing its clinical adoption. Backed by growing evidence of its efficacy, ctDNA is set to experience significant expansion, solidifying its role as a key industry driver..
Major companies operating in Global Breast Cancer
Liquid Biopsy Testing Devices Market are:
- A Menarini AG
- NeoGenomics Laboratories Inc
- F Hoffmann-La Roche AG
- Myriad Genetics Inc
- QIAGEN NV
- Biocept Inc
- Sysmex Corp
- Fluxion Biosciences Inc
- Thermo Fisher Scientific Inc
- Epic Sciences Inc
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The global breast cancer liquid biopsy testing
devices market is poised for significant growth, driven by emerging trends that
include personalized medicine, MRD monitoring, early detection, technology
advancements, integration with conventional diagnostics, telemedicine, ethical
considerations, and expanding clinical utility. As these trends continue to
evolve, liquid biopsy testing devices will become even more indispensable tools
in the fight against breast cancer, offering improved patient outcomes and more
efficient healthcare practices. The future holds great promise for this
innovative approach to breast cancer diagnosis and monitoring,” said Mr. Karan
Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“Breast Cancer Liquid Biopsy Testing Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offerings (Assay & Reagents Kits, Instruments), By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles), By Application (Cancer Applications, Non-Cancer Applications), By Region, and By Competition 2020-2030F”, has evaluated
the future growth potential of Global Breast Cancer Liquid Biopsy Testing
Devices Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Breast Cancer Liquid
Biopsy Testing Devices Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com